• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Genprex Inc.

    4/1/25 6:50:05 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNPX alert in real time by email
    NT 10-K 1 gnpx20250401_nt10k.htm FORM NT 10-K gnpx20250401_nt10k.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 12b-25

    SEC FILE NUMBER

       

    001-38244

         
       

    CUSIP NUMBER

     

    NOTIFICATION OF LATE FILING

    372446203

     

    (Check one):

    ☒  Form 10-K

    ☐ Form  20-F

    ☐ Form  11-K

       
     

    ☐  Form 10-Q

    ☐ Form  10-D

    ☐ Form  N-CEN

    ☐  N-CSR

     

     

    For Period Ended: December 31, 2024

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

     

    For the Transition Period Ended:

       

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     


     

    PART I - REGISTRANT INFORMATION

     

    Genprex, Inc.

    Full Name of Registrant

     

    N/A

    Former Name if Applicable

     

    3300 Bee Cave Road, #650-227

    Address of Principal Executive Office (Street and Number)

     

    Austin, TX 78746

    City, State and Zip Code

     

     

     

     

    PART II - RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

     

    (a)

    The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

         

    ☒

    (b)

    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

         
     

    (c)

    The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Genprex, Inc., a Delaware corporation (the “Company”), was unable to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Form 10-K”) by the prescribed due date without unreasonable effort or expense because of the circumstances described below.

     

    The Company has worked diligently to complete and finalize the 2024 Form 10-K, including the Company’s financial statements to be included therein and related audit procedures necessary for the issuance of such financial statements, so that the 2024 Form 10-K could be filed as soon as possible. However, additional time was required for the Company to complete and finalize the 2024 Form 10-K and the Company’s financial statements.

     

    In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, and as stated in Part I above, the Company represents that the subject 2024 Form 10-K will be filed on or before the fifteenth calendar day following the prescribed due date.

     

    PART IV - OTHER INFORMATION

     

    (1)

    Name and telephone number of person to contact in regard to this notification

     
     

    Ryan Confer

     

    (512)

     

    537-7997

     

    (Name)

     

    (Area Code)

     

    (Telephone Number)

     

    (2)

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

     
     

    Yes ☒ No ☐

       

     

     

     

     

    (3)

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     
     

    Yes ☐ No ☒

     
     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     


     

    Genprex, Inc.

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date:

    April 1, 2025

     

    By:

    /s/ Ryan Confer

           

    Name: Ryan Confer

    Title: President, Chief Executive Officer,

    and Chief Financial Officer

     

     
    Get the next $GNPX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

      Presentation to Highlight Genprex's Study of Reqorsa® Gene Therapy in Combination with Tecentriq® for the Treatment of Extensive Stage Small Cell Lung Cancer AUSTIN, Texas, May 29, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has been selected to present at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago, Illinois and online. Ge

      5/29/25 7:00:00 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

      Novel Gene Therapy is Addressing Both Type 1 and Type 2 Diabetes AUSTIN, Texas, May 28, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that its research collaborators presented positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate, in an oral presentation at the American Society of Gene and Cell Therapy's (ASGCT) 28th Annual Meeting which took place May 13-17, 2025 in New Orleans, Louisiana.

      5/28/25 7:00:00 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

      Advances Relationship and Collaboration with the University of Pittsburgh of the Commonwealth System of Higher Education AUSTIN, Texas, May 7, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that following the recent completion of its two-year Sponsored Research Agreement (SRA) with the University of Pittsburgh of the Commonwealth System of Higher Education (Pitt) to study Type 1 diabetes (T1D) and Type 2 diabetes (T2D), the parties have entered into a new SRA to study GPX-002, the Company's gene therapy for diabetes, in T1

      5/7/25 7:00:00 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

      Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas, May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company's co-founder and previous Chairman Rodney Varner. Prior to his appointment as Chairman,

      5/13/24 8:31:00 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

      Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer AUSTIN, Texas, Aug. 22, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the appointment of Suzanne Thornton-Jones, Ph.D. as Senior Vice President, Regulatory Affairs. Dr. Thornton-Jones will leverage her regulatory expertise to guide and oversee the Company's regulatory submissions and strategy

      8/22/23 7:30:00 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNPX
    SEC Filings

    See more
    • SEC Form S-1 filed by Genprex Inc.

      S-1 - Genprex, Inc. (0001595248) (Filer)

      5/14/25 8:51:24 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Genprex Inc.

      10-Q - Genprex, Inc. (0001595248) (Filer)

      5/12/25 4:31:16 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Genprex, Inc. (0001595248) (Filer)

      5/7/25 7:30:09 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Genprex Inc.

      SC 13G/A - Genprex, Inc. (0001595248) (Subject)

      10/24/24 12:23:37 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Genprex Inc.

      SC 13G - Genprex, Inc. (0001595248) (Subject)

      10/22/24 12:01:59 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Genprex Inc.

      SC 13G - Genprex, Inc. (0001595248) (Subject)

      10/3/24 10:09:50 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Berger Mark Stanley covered exercise/tax liability with 585 shares, decreasing direct ownership by 3% to 22,471 units (SEC Form 4)

      4 - Genprex, Inc. (0001595248) (Issuer)

      2/19/25 8:01:36 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO and CFO Confer Ryan M. covered exercise/tax liability with 395 shares, decreasing direct ownership by 1% to 38,743 units (SEC Form 4)

      4 - Genprex, Inc. (0001595248) (Issuer)

      2/19/25 8:00:01 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Moreno Toscano Jose Antonio was granted 4,750 shares, increasing direct ownership by 153% to 7,845 units (SEC Form 4)

      4 - Genprex, Inc. (0001595248) (Issuer)

      12/6/24 5:55:11 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • National Securities initiated coverage on Genprex with a new price target

      National Securities initiated coverage of Genprex with a rating of Buy and set a new price target of $7.00

      1/26/21 7:48:53 AM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care